The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.

Lantern Pharma Newsletter September 2022

In the second edition of the Lantern Pharma Newsletter you will find:

  • Phase 2 Harmonic™ clinical trial for LP-300 continues momentum with the activation of two cancer center sites and the launch of a patient-focused website
  • Lantern Pharma to host KOL webinar Sept. 22nd for Childhood Cancer Awareness Month
  • RADR® insights lead to accelerating the development of Actuate Therapeutics drug candidate Elraglusib
  • Scientific and investor conferences Lantern will be attending in Q3/Q4